GLP-1 makers are facing hundreds of law suits over vision loss side effect
GLP-1 drugs have become a major part of the U.S. market for diabetes and weight loss treatment, with brands such as Ozempic, Wegovy, Mounjaro, and Zepbound drawing nationwide demand. That broader growth is now colliding with litigation, as manufacturers including Novo Nordisk and Eli Lilly face hundreds of lawsuits over reported vision loss. The cases focus on whether the drugs were linked to serious eye injuries and whether patients were adequately warned before using them.
Lawsuits are building against major GLP-1 manufacturers
Novo Nordisk and Eli Lilly are facing a fast-growing wave of product liability lawsuits tied to GLP-1 medications, according to court filings reviewed as of September 2026. Those cases involve drugs including Ozempic and Wegovy from Novo Nordisk, along with Mounjaro and Zepbound from Eli Lilly. Plaintiffs said they experienced vision loss after taking the medicines, and the litigation now totals in the hundreds across U.S. courts.
The legal claims center on reported injuries involving eyesight, including sudden or severe vision problems described in complaints filed in federal and state venues. Court records confirm the lawsuits have been brought by patients from multiple parts of the country, though a single final count changes as new filings are added. Neither company has publicly confirmed liability in the cases now moving through the court system.
What is confirmed so far about the U.S. impact
What is confirmed is the scale of the litigation and the fact that it involves nationally distributed prescription drugs used by millions of Americans. Court filings show the cases are not limited to one state or one health system, and they involve several of the most recognizable GLP-1 brands on the market. That gives the dispute broad relevance for patients, prescribers, insurers, and pharmacies across the country.
What is not yet known is how many of the reported eye injury cases will hold up medically or legally as the lawsuits advance. The manufacturers have not released a comprehensive public list of every lawsuit or every patient injury named in the filings. There also is no final court ruling at this stage establishing that the drugs caused vision loss in the individual cases now pending.
Why these cases are moving forward and what patients may see next
The lawsuits are moving forward because GLP-1 drugs became widely used in a short period, which increased scrutiny of possible side effects as patient use expanded. Those medicines first gained broad attention through their diabetes treatment role, then saw even larger demand through weight-loss prescribing in the U.S. market. As usage climbed, reported adverse events involving the eye drew legal attention and prompted more patients to file claims.
For patients and families, the practical takeaway is that the court fight is still in an early fact-finding stage in many cases. No nationwide outcome has been set, and no final damages ruling has been issued across the hundreds of filings now underway. For now, the legal process is focused on sorting out medical evidence, warning labels, and company responsibility as the cases continue through U.S. courts.
